期刊
THORACIC CANCER
卷 12, 期 22, 页码 3068-3071出版社
WILEY
DOI: 10.1111/1759-7714.14175
关键词
adenocarcinoma; ROS1 rearrangement; small cell transformation
ROS1 rearrangement is a significant factor in non-small cell lung cancer (NSCLC). Small cell transformation plays a role in ROS1 resistance, emphasizing the importance of tissue biopsy for patients with ROS1 TKI resistance.
C-ros oncogene 1 receptor tyrosine kinase (ROS1) rearrangement has been detected in patients with advanced non-small cell lung cancer (NSCLC). Although ROS1 tyrosine kinase inhibitors (TKIs) provide a survival benefit for patients with ROS1-rearranged advanced NSCLC, subsequent therapy remains limited. Small cell transformation is an important mechanism of drug resistance in epidermal growth factor receptor-mutant NSCLC. However, its significance in mediating ROS1 resistance has not been determined yet. Here, we present the case of a 63-year-old man with ROS1-rearranged advanced NSCLC who had disease progression with small cell transformation of the mediastinal lymph node after 8 months of treatment with crizotinib. More importantly, fluorescence in situ hybridization of post-progression tumor biopsy demonstrated retention of ROS1 rearrangement. Tissue biopsy remains indispensable for patients who acquire resistance to ROS1 TKIs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据